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1. Introduction 
Emergency doctors provide primary care to many patients with an acute-onset condition in 
the emergency room (ER) every day. We occasionally must address circulatory failure in 
patients that ranges from “acutely developing” to “severe.” Usually, it is not difficult to 
diagnose or to choose the proper therapeutic procedures, because most of these cases are 
caused by heart diseases, such as ischemic heart disease or an arrhythmia. However, in 
some cases the causes of circulatory failure cannot be determined immediately. 
It is known that cardiomyopathies account for some of those undiagnosed cases. 
Classically, cardiomyopathies have been regarded as idiopathic myocardial diseases 
because of the difficulty of detecting their etiology or the mechanisms causing the 
problem. Recent developments in biochemical technology have provided the option of 
approaching these unknown mechanisms using genetic analyses (Richardson et al., 1996). 
Cardiomyopathies are presently classified into several groups, defined by the cause, 
tissue type, and clinical course. In 2006, a committee of the American Heart Association 
(AHA) advocated new criteria for cardiomyopathies. With those criteria, primary 
cardiomyopathies are classified into a genetic type, a mixed type, and an acquired type 
(Maron et al., 2006). 
We encounter several types of cardiomyopathy in the ER. Immediate adequate primary 
treatment of these cases must be prudent because circulatory insufficiency can rapidly 
progress to cardiac arrest.  
In most cases, myocarditis is caused by an inflammatory response and is classified as an 
acquired type of primary cardiomyopathy. It is also categorized as either acute or chronic. 
The comprehensive concept of chronic myocarditis has not yet been established because 
cases of chronic myocarditis have not been sufficiently reported. For most cases of chronic 
myocarditis, the causes and developmental mechanisms remain unclear. 
We have only practical guidelines for treating chronic myocarditis in Japan (JCS, 1996). 
These patients usually have long-term therapeutic histories. Therefore, the patients’ own 
doctors who are familiar with their clinical histories should be responsible for treatment in 
the ER. On the other hand, most cases of acute myocarditis are of sudden onset, and severe 
cases are taken to the ER by the emergency medical service. Doctors in the ER must then be 
responsible for the primary treatment of these patients. Because there is the risk of sudden 
development of circulatory insufficiency with acute myocarditis, immediate and adequate 
initial treatment is necessary for survival. 
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In this chapter, we explain the causes, mechanisms as presently known, classification, and 
clinical course of myocarditis. Additionally, we outline the recommended treatment for the 
acute phase of myocarditis. 
2. Epidemiology and prognosis  
The clinical course of myocarditis varies. The symptoms range widely, from slight to severe, 
and it is difficult to investigate myocarditis epidemiologically. In 2002 in Japan, a large-scale 
investigation for cardiomyopathy was performed and reported that cardiomyopathy was 
found in 21.3 per 100,000 population (Miura et al., 2002). However, the subjects of this 
investigation were consulted patients with data provided by hospitals. It is thought that 
actual morbidity is higher, because there are many non-consulted persons with occult 
cardiomyopathy, such as early stage dilated cardiomyopathy or hypertrophic 
cardiomyopathy with no symptoms. Therefore, we still cannot grasp the exact morbidity of 
myocarditis in Japan. Okada et al. (1989) reported that among 10,000 autopsied cases during 
1958–1978 there were 115 cases of myocarditis. In another report, occult myocarditis was 
found in 0.6% of autopsied cases in which cardiac disease had not detected while the 
patients were alive (Feely et al., 2000). Therefore, it should be recognized that myocarditis is 
not clinically infrequent and includes a mild type that displays no symptoms. The mortality 
rate for myocarditis has not been established. An investigative committee of the Ministry of 
Public Welfare and Labor in Japan reported in 1986 that 13 (4.7%) of 274 patients died 
within 1 month in a small-scale investigation targeting acute-phase myocarditis (Kawamura 
et al., 1986). Among those cases, the causes of death were cardiogenic shock in six cases 
(46%), congestive heart failure in five cases (38%), and complete atrioventricular block in 
two cases (15%). Intensive treatment for severe cardiac dysfunction and fatal arrhythmias 
are important to reduce mortality during the acute phase of severe myocarditis. 
3. Cause of myocarditis and classification  
Myocarditis is classified by cause, clinical type, and pathological picture. In clinical 
medicine, myocarditis presenting as a sudden development should be attended to because 
any delay of treatment presents a risk of fatal circulatory failure. It should be recognized 
that there is different prognosis depending on the clinical type of myocarditis. The 
classification of myocarditis is shown in Table 1. 
3.1 Causes 
Several causes or mechanisms of the development of myocarditis have been detected, 
among which infection is the most the frequent and important. In earlier years, myocarditis 
was often caused by rheumatic fever and diphtheria. More recently, in advanced nations it 
is mostly caused by viral infections. Bowles et al. (1986) reported that Coxsackie B virus was 
detected in patients with myocarditis using a dot blot hybridization method. Coxsackie 
virus, an enterovirus belonging to the picornavirus family, was extracted from patients with 
polio in 1982 and is particularly compatible with myocardium (Clements, 1993). Half of 
group A types and all of group B types of the Coxsackie virus cause myocarditis 
accompanied by symptoms of the common cold.  
Presently, it is possible to detect many viruses with polymerase chain reaction or in situ 
hybridization. Therefore, we can detect myocarditis due to viral infection in most cases. In 
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Causes Histological classification Clinical classification 
Infection Lymphocytic myocarditis Acute type 
Virus Giant cell myocarditis Fulminant type 
Bacterium Eosinophilic myocarditis 
Chronic type 
(including persistent symptoms 
type and unremarkable 
symptoms type) 
Fungus 
Granulomatous 
myocarditis 
Rickettsia 
Spirochete 
Parasite 
Others 
Drugs, chemical 
materials 
Allergy, autoimmunity 
Collagen disease 
Kawasaki disease 
Sarcoidosis 
Radiation 
Heat stroke 
Unknown (idiopathic) 
Table 1. classification of myocarditis. modified from the guideline for the diagnosis and 
treatment of myocarditis (JCS, 2005). 
 
 
1. Nonsteroidal anti-inflammatory drugs 
          Indomethacin, oxyphenbutazone, phenylbutazone 
2. Psychotropic drugs 
          (Tricyclic) antidepressant: imipramine, clomipramine, amitriptyline 
          Antimanic: lithium carbonate, lithium oxalic acid 
          Antiepileptic: phenytoin, carbamazepine 
3. Diuretic: acetazolamide, hydrochlorothiazide, spironolactone, chlorthalidone 
4. Depressor: methyldopa 
5. Anticancer drug: adriamycin, daunorubicin, mitoxantrone 
6. Antibiotics  
          Amphotericin B, penicillin, ampicillin, tetracycline  
          Chloramphenicol, streptomycin  
7. Sulfaminum: sulfadiazine, sulfisoxazole 
8. Antiphthisic: isoniazid (INH), para-aminosalicylic acid (PAS) 
9. Biological agents: tetanus toxoid, α-interferon, interleukin 2 (IL-2) 
10. Antidiabetic: sulfonylurea 
11. Others: catecholamines, cocaine, amphetamine, arsenic 
Table 2. Drugs that cause myocarditis. 
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recent reports, adenovirus, sharing the same receptors as the Coxsackie virus, parvovirus 
B19, human herpes virus 6, and hepatitis C virus, are known to cause myocarditis (Okabe et 
al., 1997). 
Myocarditis does not always develop in patients infected by a virus compatible with the 
myocardium (e.g., the Coxsackie virus). In such cases, symptoms of myocarditis are 
unremarkable or slight, and the mechanism of development of myocarditis remains 
unknown. Based on the results in experimental animal models, Cupta et al. (2008) suggested 
a developmental pattern of myocardial damage by an infective virus and the host’s reactions 
as follows: (1) initial infection of virus in myocardial cells; (2) innate immune reaction; (3) 
defense by adaptive immunity; and (4) recovery of inflammatory reaction. 
Several kinds of drugs, external physical stimulations such as exposure to irradiation or 
excessive heat, metabolic disorders, pregnancy, collagen diseases, sarcoidosis, and Kawasaki 
disease are important causes of myocarditis. It should be well noted that drug-induced 
myocarditis, particular in Japan, Europe, and the United States, is caused by many of the 
drugs that are administered or prescribed to patients in advanced countries. Drugs that 
cause myocarditis are shown in Table 2. 
3.2 Histological classification 
Histologically, myocarditis is classified as lymphocytic myocarditis, giant cell myocarditis, 
eosinophilic leukocyte myocarditis, and granuloma myocarditis. Most cases of lymphocytic 
myocarditis are caused by infection. Other types are due to materials toxic to the 
myocardium, a drug allergy, or an autoimmune reaction. 
3.2.1 Lymphocytic myocarditis 
Lymphocytic myocarditis is the most frequent histological type, and most cases are caused 
by a viral infection. Kodama et al. found that 85% of patients with myocarditis were 
diagnosed with the lymphocytic variety (Kodama et al., 2001). The primary 
symptomsfever and pharyngeal painare not specific for myocarditis during the early 
phase, but symptoms of circulatory failure, such as edema, are specific and are observed 
during the developed phase. The severity of circulatory failure ranges widely from slight to 
fulminant. 
3.2.2 Giant cell myocarditis 
Giant cell myocarditis is encountered infrequently. Clinically, it has a poor prognosis 
because it can easily progress to fulminant myocarditis. After the onset, circulatory failure 
develops suddenly and in many cases rapidly progresses to a fatal state. It is suggested that 
an allergic reaction or an autoimmune reaction participates in this development. Infiltration 
by inflammatory cells and multinucleated cells are observed in the myocardium (Davidoff et 
al., 1991). Cardiac function markedly deteriorates with massive necrosis of the myocardium. 
Identification of multinucleated cells is necessary for a definitive diagnosis. It is difficult to 
decide on the timing of a biopsy because multinucleated cells are seen only during the acute 
phase. In patients presenting with a chronic course, cardiac sarcoidosis must be excluded 
(Shield et al., 2002). 
3.2.3 Eosinophilic myocarditis 
The clinical symptoms of eosinophilic myocarditisfever, pharyngeal pain, coughduring 
the early phase are similar to those seen with myocarditis due to a viral infection. The 
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differential diagnosis between viral myocarditis and eosinophilic myocarditis is often 
impossible because the eosinophil count is normal during the early phase of eosinophilic 
myocarditis (Morimoto et al., 2003). White blood cells (WBCs) gradually increase with the 
development of an inflammatory reaction; and materials toxic to the myocardium released 
from eosinophilic leukocytes cause severe contraction of the myocardium as the eosinophil 
count exceeds 500/nm3. 
In most cases, the increase in eosinophils is detected in a peripheral blood examination. 
However, some patients who suffer from circulatory insufficiency exhibit a delayed increase 
in eosinophils (Gets et al., 1991). Therefore, we should perform more frequent  eosinophil 
counts during the acute phase. Infiltration of eosinophilic leukocytes, degranulation, and 
destruction of myocardium are observed in the biopsy specimen.  
The main causes are an allergic reaction, drugs, and parasitic infection. Most cases, however, 
are treated as idiopathic myocarditis (Forrester et al., 1976). It has been reported that the 
mortality rate among patients with acute-phase eosinophilic myocarditis is approximately 
7% (Morimot et al., 2003), (Mori et al., 2004). 
3.3 Clinical classification 
Myocarditis is clinically classified as acute or chronic. Since it is possible to detect the exact 
onset of acute myocarditis, it is easier to estimate the circulatory parameters for diagnosis 
and establish the strategy for treatment of acute myocarditis than for chronic myocarditis. In 
some cases of acute myocarditis, we treat it as fulminant myocarditis that has developed 
suddenly and may progress to severe circulatory failure during the acute phase (Aoyama et 
al., 2002). The worldwide morbidity and mortality rates associated with fulminant 
myocarditis are not yet clear. Cupta et al. (2008) reported that the frequency of fulminant 
myocarditis is 10% among all cases of acute myocarditis in the United States. 
The global concept of chronic myocarditis has not been established, although several studies 
have suggested that viral infection (Fujioka et al., 2000) or autoimmunity (Lauer et al., 2000) 
play a role in its development. There are clinically two types of chronic myocarditis, and 
they have different clinical courses. One type has persistent, continuous symptoms, and the 
other has unremarkable symptoms (JCS, 1996). 
In an investigation of clinical types of myocarditis in 48 patients reported by Kodama et al. 
(2001), nine were the acute type, 21 were the fulminant type, three were the chronic 
persistent symptom type, and 15 were the chronic unremarkable symptom type. The 
mortality rates during the first admission were 22% for the acute type, 43% for the fulminant 
type, 33% for the chronic persistent symptom type, and 40% for the chronic unremarkable 
symptom type. The long-term prognosis for patients who recovered from their cardiac 
dysfunction during the early phase was good. However, the long-term prognosis for 
patients who were diagnosed with the chronic, unremarkable symptom type was not good 
because they developed irreversible circulatory dysfunction, such as dilated 
cardiomyopathy.  
4. Clinical symptoms and diagnosis 
4.1 Clinical symptoms and physical symptoms 
Clinically, symptoms range from slight problemsfever, pharyngeal pain, cough, vomiting, 
diarrhea, and arthropathies, as observed with the common coldto severe circulatory 
failure. Therefore, we cannot list any symptoms characteristic of acute-phase myocarditis. In 
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cases of established cardiac dysfunction, patients suffer from dyspnea, edema, cyanosis, 
palpitations due to hypoxia or arrhythmia, and other severe symptoms such as loss of 
consciousness and cramping. Whenever we treat acute-onset patients who present with 
symptoms of cardiac dysfunction in the ER, we maintain the suspicion that they are in the 
pre-developmental phase of severe myocarditis. 
Among the physical symptoms of myocarditis, dysfunction of the heart’s conduction 
system, which occurs in 60%–80% of patients with myocarditis, is critical. Particularly 
notable is the 30% incidence of severe bradycardia requiring temporary pacing in those 
with fulminant myocarditis (Kawamura et al., 1986). A galloping rhythm, a heart 
murmur caused by backflow in the atrioventricular valves, and pulmonary moist rales 
are found in patients who are developing heart failure. Pericardial and pleural 
stridulation can be auscultated in patients with pericarditis or pleuritis. Furthermore, 
pericardial effusion or cardiac tamponade is observed in some cases of developmental 
pericarditis. 
4.2 Blood examinations 
Inflammatory reactions such as increased WBCs, an increased erythrocyte sedimentation 
rate (ESR), or an increased C-reactive protein (CRP) level are detected in blood examinations 
during the early phase. Additionally, creatine kinase MB (CPK-MB) and cardiac troponin T 
assays, which are elevated in the presence of myocardial damage, are useful. Troponin T 
sensitivity is particularly high, and the severity of the myocardial damage can be estimated 
by a fixed quantity analysis (Lauer et al., 1997). Troponin T continuously increases with 
development of cardiac dysfunction and maintains a high peak value in those with 
fulminant myocarditis. 
4.3 Chest radiography 
Cardiac dilatation is present in 70% of chest radiography examinations, and pulmonary 
congestion or pleural effusion is often present in patients with severe heart failure. It should 
be noted that cardiac dilatation and pulmonary congestion are not remarkable in some cases 
of myocarditis, which causes mainly right ventricular failure (McFalls and van Suylen, 
1993).  
4.4 Electrocardiography 
Various abnormal changes are revealed by electrocardiography (ECG), although none of the 
changes are specific for myocarditis. ECG is not an invasive procedure, and it has the benefit 
of simplicity of performance. The sensitivity is high, and any changes on the ECG tracing 
probably enhance with the development of myocarditis even if only slight changes are 
detected during the early phase. ECG should be repeated in the case of suspected 
myocarditis. Limited elevation of ST-T, mainly observed with acute myocardial infarction 
(AMI), is present in some patient with myocarditis. Elevation of ST-T in all leads is present 
in cases complicated by pericarditis. Bundle branch block or atrioventricular block is present 
in cases complicated by dysfunction of the heart’s conduction system. It should be noted 
that the change to a wide QRS complex on the ECG tracing suggests the development of 
cardiac dysfunction. Because there is the risk of sudden changes with fatal ventricular 
tachycardia (VT) or ventricular fibrillation (VF) in the case of frequent arrhythmias, 
continuous ECG monitoring is necessary.  
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4.5 Echocardiography 
Temporal thickening of the ventricular wall and deterioration of ventricular wall motion are 
present at inflammatory sites. All-round centripetal thickening, diffuse deterioration of wall 
motion, and stenosis of the intracardiac space are present in typical cases (Hiramatsu et al., 
2001). In the cases of severe circulatory failure or fulminant myocarditis, multiple left 
ventricular thrombi are frequently caused by the deterioration of all-round wall motion. 
Continuous wall motion dysfunction causes diffuse thinning of the wall and/or ventricular 
aneurysms, and dilatation of the left ventricle develops. Ultimately, there is no 
morphological difference from dilated cardiomyopathy. Diagnosis by exclusion of ischemic 
heart disease is necessary in patients with wall thickening or wall motion deterioration. 
4.6 Cardiac magnetic resonance  
Cardiac magnetic resonance (CMR) is a noninvasive, useful examination for myocarditis 
(JCS, 2011). It can be used to estimate the morphological changes in the ventricles, 
contractive function, perfusion in the myocardium, and histological characteristics in one 
performance. In myocarditis, hyperemia and capillary leakage in the cardiac 
microcirculation are caused by an inflammatory reaction. The site of inflammation in the 
myocardium has high signal intensity on T1-weighted magnetic resonance imaging (MRI) 
several minutes after gadolinium contrast enhancement during the acute phase. It is 
suggested that the changes of microcirculation caused by an inflammatory reaction can be 
directly visualized with CMR (Friedrich et al., 1998). In many cases, widespread edema in 
the myocardium is caused during the acute phase. High signal intensity on T2-weighted 
images is present in 36% of myocarditis diagnosed by the Dallas criteria (Aretz et al., 1987), 
(Mahrholdt et al., 2004). In those patients, follow-up CMR, performed a year later, shows 
reduced left ventricular capacity (Zagrosesek et al., 2008). We can predict the histological 
changes and prognosis for cardiac function using CMR. 
4.7 Radioisotope examination 
Gallium-67 (67Ga) is specific for infiltration of large monocytes, but it does not have high 
sensitivity (O’Connel et al., 1984). Pyrophosphate scintigraphy using technetium-99m 
(99mTc) is sensitive and accumulates at the inflammatory site in the myocardium (Morguet et 
al., 1994). 
4.8 Cardiac catheterization and endomyocardial biopsy  
We perform cardiac catheterization for the differential diagnosis during the acute phase if 
the patient’s circulatory condition can tolerate it. We first exclude significant coronary 
stenosis by coronary angiography and then perform endomyocardial biopsy (Sekiguchi et 
al., 1980). The endomyocardial biopsy is now the most important and reliable technique for 
a definitive diagnosis. However, we often cannot obtain samples of the lesion site because 
the inflammatory reaction in the myocardium occurs inhomogeneously in most cases 
(Baughman, 2006). Cooper et al. (2007) reported that cardiac tamponade or ventricular 
perforation occurs at the time of sampling with a 0.1%–0.5% frequency. 
4.9 Detection of viruses 
In cases of suspected viral myocarditis, we measure the antibody titer using paired sera 
collected at a more than a 2-week interval. The reliable positive ratio is only 10%, and the 
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capability to detect infected organs is not available. A definitive diagnosis is possible if we 
can directly detect the original viruses using a polymerase chain reaction or in situ 
hybridization. However, these techniques are not yet approved as standard examinations 
because their results vary widely depending on the institution in which they are performed. 
4.10 Other diagnostic factors 
In cases of suspected drug-induced myocarditis, we narrow down the list of causative drugs 
by detailed interviews with the patient regarding his or her clinical history. We can then 
identify the causative drug by a drug-induced lymphocyte stimulation test. Soluble Fas and 
Fas ligand (Fuse et al., 2000), interleukin-10 (Nishii et al., 2004), and tenascin-C (Imanaka-
Yoshida et al., 2002) may be used in upcoming tests for diagnosing myocarditis. 
Guidelines for diagnosis are presented in Table 3. The basic concept is to exclude ischemic 
heart disease and confirm an active lesion site by endomyocardial biopsy. It is currently 
impossible to detect the cause in most cases. Clinically, it is best to provide the primary care 
that is given to patients suspected of having myocarditis caused by a viral infection. 
5. Development and strategy for treatment during the acute phase 
Generally, the clinical conditions of patients are similar in many cases of myocarditis. A 
toxic protein produced by the infecting virus destroys the myocardial dystrophin complex 
within several days after onset of the myocarditis. It has been noted that this mechanism 
causes severe myocardial dysfunction accompanied by widespread myocardial cell death 
(Bandorff et al., 1999). Silver and Kowaldzuk (1989) reported that viral infection directly 
causes widespread myocardial ischemia by microvascular spasm.  
After the viral infection is established, the immune response produces inflammatory 
cytokines in large quantities (Fairweather et al., 2005). This cytokine network originally 
plays a role in prophylaxis against the viral infection. Inflammatory cytokines such as 
interleukins 1 and 2 and tumor necrosis factor-α eliminate infected viruses by activating 
macrophages, lymphocytes, and endothelial cells. However, excessive cytokine release 
damages myocardial cells and causes myocardial dysfunction (Kawai, 1999). Additionally, 
inducible nitric oxide (NO) synthase (iNOS) induced by activated macrophages acts to 
encourage NO to eliminate infected viruses. It has been reported that excessive release of 
NO strongly damages myocardial cells (Mikami et al., 1996). 
Infiltration by inflammatory cells, including T cells and natural killer cells, peaks 7–14 days 
after viral infection and causes widespread necrosis of myocardial cells (Seko et al., 1993). 
As already noted, infected virus and released inflammatory cytokines are the main 
mechanisms in the development of myocardial dysfunction during the acute phase. Severe 
deciduation of myocardial cells causes pump failure, which progresses to fatal circulatory 
collapse. 
It is important to remember that cardiac dysfunction associated with myocarditis is 
reversible in many cases. Full recovery of cardiopulmonary function can be expected if the 
patient’s life support is adequately performed. Therefore, we compress the strategy for 
treatment into three stages to give patients suffering from myocarditis the best chance for 
survival. 
In most cases, the first strategic issue is intervention regarding the cause. Unfortunately, it is 
impossible to provide antibiotic therapy because effective antiviral drugs to address viral 
myocarditis have not been developed. There is a risk of further viral propagation when 
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1. Primary symptoms (nonspecific symptoms in most cases) 
 Symptoms that appear with the common cold (fever, headache, cough, pharyngeal 
pain) 
 Digestive symptoms (nausea, vomiting, diarrhea, abdominal pain) 
 Others (eruption, arthralgia, myalgia) 
 Note: Some patients are found in sudden cardiac arrest 
2. Physical findings 
 Tachycardia, bradycardia, arrhythmia, weak heart sounds 
 Galloping rhythm (III, IV sounds), pericardial friction murmur 
 Systolic murmur 
3. Abnormality of ECG: various changes 
 Atrioventricular block, wide QRS complex, reduction of height in R wave, abnormal 
Q wave 
 Change of ST-T level, low-voltage wave, frequent premature contractions 
 Supraventricular tachycardia, atrial fibrillation, sinus arrest 
 Ventricular tachycardia, ventricular fibrillation, asystole 
4. Echocardiography 
 Focal or diffuse thickening of the ventricular wall 
 Focal or diffuse deterioration of ventricular wall motion 
 Stenosis of intracardiac space 
 Pericardial effusion 
5. Blood examinations 
 Detection of creatine kinase MB (CPK-MB) 
 Detection troponin T 
 Inflammatory reaction (increased WBCs, CRP level) 
 Note: Troponin T is sensitive using whole blood during the acute phase 
6. Items 2–5 (above) change within several hours. Therefore, continuous observation is 
necessary. Bradycardia, wide QRS complex, frequent premature contractions, 
enhanced thickening of the ventricular wall and deterioration of ventricular wall 
motion, and continuous high troponin T levels are dangerous symptoms of fatal 
circulatory crisis. 
7. A differential diagnosis of acute myocardial infarction (AMI) is necessary. 
8. Endocardial biopsy provides a definitive diagnosis, but AMI cannot be excluded if 
tissue images are not obtained. 
 Diagnostic criteria in tissue image: 
 Infiltration of large and small monocytes 
 Rupture, fusion, or disappearance of myocardial cells 
 Edema or fibrotic changes in interstitial tissue 
9. More than four-fold change of viral antibody titer in paired sera is adequate for viral 
detection. Polymerase chain reaction is effective for diagnosing a viral infection. 
Additionally, virus isolation or detection of viral antigen from a throat swab, urine, 
feces, blood, or particularly pericardial effusion or myocardial tissue are direct 
evidence of the diagnosis. 
Table 3. Guidelines for diagnosing myocarditis. Modified from the guideline for diagnosis 
and treatment of myocarditis (JCS, 2005). 
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administering anti-inflammatory drugs such as immunosuppressants and steroids. On the 
other hand, we can expect to reverse cardiac dysfunction by initially giving anti-
inflammatory drugs because it has been reported that allergic and autoimmune reactions 
strongly participate in the development of the giant cell myocarditis and eosinophilic 
myocarditis, both unusual forms. Therefore, early and adequate ascertainment of the cause 
is the maximum priority. Presently, the performance of myocardial biopsy is limited. 
Steroids should not be selected as a first choice even if the patient is in a shock state. 
The second issue is to provide cardiopulmonary support during continuing fatal circulatory 
failure. During the acute phase of severe myocarditis, there is the risk of cardiogenic shock, 
complete atrioventricular block, fatal arrhythmia, and/or sudden cardiac arrest at any time. 
Therefore, most patients require intensive care. Drug therapy for myocarditis is no different 
from that for usual heart failure. Catecholamines, a diuretic, or both are administered 
following Forrester’s classification. Mechanical cardiopulmonary life support should be 
immediately introduced when the circulatory insufficiency cannot be reversed with drugs. 
Full recovery of cardiac function is expected by advanced life support within several days in 
patients with acute myocarditis. 
The third issue is to control the inflammatory reaction. If the actions of excessive 
inflammatory cytokines and NO are reduced, cardiac dysfunction is expected to be reversed 
during the acute phase. Although treatment using high doses of steroid, high doses of γ-
globulin, and plasma exchange have been tried and evaluated, we have no evidence of their 
effectiveness. 
5.1 Cardiopulmonary support 
Immediate cardiac resuscitative support must be provided if the patients with fulminant 
myocarditis are to survive. Delay of treatment results in fatal circulatory collapse. Although 
the short-term mortality rate for fulminant myocarditis is generally high, the long-term 
functional prognosis for patients who survive the acute circulatory crisis is good compared 
with that for dilated cardiomyopathy (McCarthy et al., 2000). 
The Scientific Committee of the Japanese Circulation performed a retrospective follow-up 
survey on severe fulminant myocarditis (Aoyama et al., 2002). The cases of 52 patients who 
required percutaneous cardiopulmonary support (PCPS) because of severe circulatory 
failure were investigated. The mortality rate for the acute phase was 40.4% (21/52). Among 
the 31 surviving patients, 30 (96.8%) had fully recovered from their cardiac dysfunction. 
McCarthy et al. (2000) noted that cardiac function had been maintained in good condition 
for a long time in more than 90% of patients who had recovered from fulminant 
myocarditis. Therefore, the “bridge” treatment of using mechanical cardiopulmonary 
support to avoid multiple organ dysfunction caused by hypoperfusion is an important 
treatment strategy during the acute phase of fulminant myocarditis. Patients who have 
survived on mechanical support, such as percutaneous cardiopulmonary support or a 
ventricular assist system, have also been reported (Chen et al, 2005), (Topkara et al., 2006). 
5.1.1 Percutaneous cardiopulmonary support  
A guideline for the use of percutaneous cardiopulmonary support (PCPS) has been 
formulated in Japan (Fig. 1) (Aoyama et al., 2002). In suspected cases of low cardiac output 
due to pump dysfunction, we may apply PCPS in accordance with continuous monitoring 
of the circulatory condition. Important clinical parameters to examine when making the 
decision of whether to use PCS include the urinary volume, SvO2 (< 60%), development of 
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Fig. 1. Modified algorithm of PCPS for fulminant myocarditis (Aoyama et al, 2002). 
metabolic acidosis, and multiple organ dysfunction suggested by blood chemistry 
examinations. The initial flow of PCPS should be established at 3.0–3.5 L/min. Concomitant 
use of intra-aortic balloon pumping (IABP) provides the benefits of reduced afterload, 
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improved peripheral circulation by pulsatile flow, and backup support at the completion of 
PCPS. It is recommended that a branched cannula be established in the distal side of the 
femoral artery for blood transfusion because there is a risk of ischemia in the lower limb. 
Unfortunately, we occasionally experience patients in severe situations in whom sufficient 
organ perfusion cannot be provided even if PCPS is fully operative. Aoyama et al. (2002) 
reported that 40% of patients supported by PCPS died during the acute phase. Among them, 
multiple organ dysfunction due to hypoperfusion was found in 25% and ischemia in the 
lower limb in 23%. Because the prognosis of fulminant myocarditis depends on the outcome 
of radical treatment of the circulation, we discuss early exchange via a ventricular assist 
system when sufficient organ perfusion cannot be provided by PCPS. 
Case report: We treated a patient with severe fulminant myocarditis who survived owing to 
emergency PCPS. The young woman consulted her family doctor because of fever and was 
prescribed anti-inflammatory drugs with a diagnosis of pharyngitis. She was admitted to 
our hospital because of sudden severe circulatory failure that required high-flow 
oxygenation and high doses of catecholamine. Blood examination showed an elevation in 
troponin I, CPK, and other cardiac enzymes. Chest radiography showed marked cardiac 
dilatation and pleural effusion (Fig. 2). Echocardiography revealed pericardial effusion and 
deterioration of all-round wall motion of the left ventricle (Fig. 3). No significant coronary 
stenosis was detected by coronary angiography. We introduced emergency PCPS with IABP 
because her left ventricular ejection fraction was decreased by less than 20%. Her circulatory 
condition dramatically recovered, and she was weaned from PCPS on the 10th day. She 
obtained full recovery of her circulatory function. We could not detect any viruses when 
measuring the antibody titer using paired sera. 
 
 
 
 
 
 
 
 
 
Fig. 2. Chest radiography shows marked cardiac dilatation and pleural effusion. 
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Fig. 3. Echocardiography shows pericardial effusion and deterioration of the all-round wall 
motion of the left ventricle. 
5.1.2 Ventricular assist system  
There is the risk of severe pulmonary congestion due to PCPS in cases of extreme 
deterioration of left ventricular function. In such cases, the patient should be switched to a 
ventricular assist system (VAS) before organ dysfunction develops. Grinda et al. (2004) 
reported that they introduced VAS in five cases of severe fulminant myocarditis and 
obtained good outcomes. Recently, the clinical effectiveness of modified VAS using an 
extracorporeally established centrifugal pump was advocated by John et al. (2007) in the 
United States. Modified VAS has combined the advantages of minimally invasive 
extracorporeal membrane oxygenation and high efficiency.  
5.2 Immunoregulation therapy 
Generally, the time limit for continuous mechanical circulatory support, including PCPS or 
VAS, is approximately 1 week. We withdraw the system even if recovery from circulatory 
failure is incomplete. In such cases, introduction of immunoregulation therapy is discussed. 
Many case reports have asserted the effectiveness of immunoregulation therapy. Although 
there is no established evidence, we believe that immunoregulation is acceptable in 
intractable cases because no radical treatments are presently available. 
5.2.1 High-dose γ-globulin 
The effectiveness of high-dose γ-globulin was reported by Takada et al. (1995). It is expected 
that γ-globulin counteracts the actions of the infective viruses and reduces suppression of 
cardiac function by inflammatory cytokines during the acute phase. γ-Globulin intensifies 
patients’ immune competence, and therefore complications, such as an infection 
compromised by steroid administration, do not take hold. The mechanisms of high-dose 
administration have not been completely clarified, although several hypotheses have been 
suggested: (1) it functions as a neutralizing antibody; (2) it has an anti-inflammatory effect, 
reducing the release of inflammatory cytokines induced by a combination of the Fc part of γ-
globulin and the suppressive Fc receptor of macrophages; and (3) it has the effect of anti-
activation on activated complement (Rosen, 1993). However, it is not strongly recommended 
because there is no evidence that has been confirmed by large clinical trials. Finally, cardiac 
function has not recovered in several cases with its use. 
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5.2.2 High-dose steroids 
The effectiveness of steroids as anti-inflammatory and immunosuppressant drugs has been 
widely accepted. Its effectiveness when treating patients with fulminant myocarditis has 
been also reported in many studies (Ino et al., 1995). However, administration of steroid was 
not proved effective in patients with lymphocytic myocarditis in a clinical trial (Mason et al., 
1995). We would not hastily administer steroids to patients with acute-phase myocarditis 
with a suspected viral infection. On the other hand, it is expected that administration of 
steroids alleviates cardiac dysfunction in patients with giant cell myocarditis and 
eosinophilic myocarditis (Cooper et al., 1997). Particularly, high-dose steroids should be 
given prior to other treatments in patients with the fulminant type of giant cell myocarditis. 
6. Conclusions 
It is not easy to explain myocarditis concisely and clearly because there are varieties of 
causes, clinical types, clinical courses, and the severity of circulatory failure. Some patients 
present with common cold-like symptoms, whereas others require mechanical circulatory 
support in the ER because of a suddenly developing circulatory crisis. Information of the 
patient’s background and clinical history is essential when deciding on a treatment plan for 
myocarditis in most cases, although we are sometimes unexpectedly confronted with 
emergency conditions regarding these patients in the ER.  
Currently, the most troublesome issue in the course of treating myocarditis is when to 
perform a myocardial biopsy for a definitive diagnosis. Although noninvasive diagnostic 
methods such as CMR have been developed to reduce the risk of serious complications 
and physical strain on the patient, an effective diagnosis cannot be established during the 
acute phase. Regarding the treatment for myocarditis, we cannot presently exclude 
original causes in many cases and can only provide unpredictable “bridge” support, such 
as PCPS or VAS. 
Many patients with myocarditis can survive if we remember the possibility of myocarditis 
in the differential diagnosis and provide immediate, adequate treatment. When we face 
illness of unknown origin in patients with a severe arrhythmia or circulatory failure, we 
should immediately assemble the medical staff and prepare cardiac support. Any delay in 
treatment can allow abrupt deterioration of the circulation. Additionally, we should 
establish a system of simultaneous processing of the histological diagnosis to decide on the 
propriety of immunoregulation therapy. 
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